Current and future therapeutic approaches in progressive supranuclear palsy

Handbook of Clinical Neurology

Volumn 89, Issue , 2008, Pages 493-508

  van Balken, Irene ^a   Litvan, Irene ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; ELECTROCONVULSIVE THERAPY; HUMAN; METABOLISM; METHODOLOGY; PHYSIOTHERAPY; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

BEHAVIOR THERAPY; DEEP BRAIN STIMULATION; ELECTROCONVULSIVE THERAPY; HUMANS; NEUROTRANSMITTER AGENTS; PHYSICAL THERAPY (SPECIALTY); SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 66049154936     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01246-8     Document Type: Review

References (171)

1. Agid Y., Javoy-Agid F., Ruberg M., et al. Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45 (1987) 191-206
2. Albanese A., and Colosimo C. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. Acta Neurol Scand 107 (2003) 349-355
3. Albers D.S., and Beal M.F. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 40 (2002) 559-564
4. Albers D.S., Augood S.J., Martin D.M., et al. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 73 (1999) 881-884
5. Albers D.S., Augood S.J., Park L.C., et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 74 (2000) 878-881
6. Albert M.L., Feldman R.G., and Willis A.L. The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37 (1974) 121-130
7. Alexander G.E., DeLong M.R., and Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9 (1986) 357-381
8. Asahina M., Suhara T., Shinotoh H., et al. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 65 (1998) 155-163
9. Asanuma M., Hirata H., Kondo Y., et al. A case of progressive supranuclear palsy showing marked improvements of frontal hypoperfusion, as well as parkinsonism with amitriptyline. Rinsho Shinkeigaku 33 (1993) 317-321
10. Barclay C.L., and Lang A.E. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62 (1997) 352-356
11. Barclay C.L., Duff J., Sandor P., et al. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 46 (1996) 1284-1286
12. Beal M.F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 36 (2002) 455-460
13. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53 (2003) S39-S47 discussion S-8
14. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36 (2004) 381-386
15. Birdi S., Rajput A.H., Fenton M., et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 17 (2002) 1255-1264
16. Blesch A., and Tuszynski M.H. Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury. Yonsei Med J 45 (2004) 28-31
17. Blin J., Mazetti P., Mazoyer B., et al. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?. Brain 118 (1995) 1485-1495
18. Brusa L., Bassi A., Lunardi G., et al. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. Eur J Neurol 11 (2004) 593-606
19. Buee L., Bussiere T., Buee-Scherrer V., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33 (2000) 95-130
20. Bugiani O., Mancardi G.L., Brusa A., et al. The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol 45 (1979) 147-152
21. Buhot M.C. Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7 (1997) 243-254
22. Cakmur R., Ozturk V., Uzunel F., et al. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 249 (2002) 64-68
23. Carrilho P.E., and Barbosa E.R. Progressive supranuclear palsy in a sample of Brazilian population: clinical features of 16 patients. Arq Neuropsiquiatr 60 (2002) 917-922
24. Chauhan N.B., Siegel G.J., and Feinstein D.L. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 48 (2005) 93-104
25. Chen J.J., and Swope D.M. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45 (2005) 878-894
26. Chiu H.F., and Li S.W. Progressive supranuclear palsy presenting with psychiatric features. Br J Clin Pract 50 (1996) 60-61
27. Choi-Kwon S., Han S.W., Kwon S.U., et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 37 (2006) 156-161
28. Collins S.J., Ahlskog J.E., Parisi J.E., et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 58 (1995) 167-173
29. Cordivari C., Misra V.P., Catania S., et al. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 16 (2001) 907-913
30. Cordivari C., Misra V.P., Catania S., et al. New therapeutic indications for botulinum toxins. Mov Disord 19 (2004) S157-S161
31. Cummings J.L. Frontal-subcortical circuits and human behavior. Arch Neurol 50 (1993) 873-880
32. D'Antona R., Baron J.C., Samson Y., et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 108 (1985) 785-799
33. DA agonists. Ergot derivatives: lisuride: management of Parkinson's disease. Mov Disord 17 (2002) S74-S78
34. Daniele A., Moro E., and Bentivoglio A.R. Zolpidem in progressive supranuclear palsy. N Engl J Med 341 (1999) 543-544
35. Davie C.A., Barker G.J., Machado C., et al. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 12 (1997) 767-771
36. Defazio G., De Mari M., De Salvia R., et al. "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy) a case report. Clin Neuropharmacol 22 (1999) 292-294
37. Dehaene I., and Bogaerts M. L-dopa in progressive supranuclear palsy. Lancet 2 (1970) 470
38. Destee A., Gray F., Parent M., et al. Obsessive-compulsive behavior and progressive supranuclear palsy. Rev Neurol (Paris) 146 (1990) 12-18
39. Diroma C., Dell' Aquila C., Fraddosio A., et al. Natural history and clinical features of progressive supranuclear Palsy: a clinical study. Neurol Sci 24 (2003) 176-177
40. Donaldson I.M. The treatment of progressive supranuclear palsy with L-dopa. Aust N Z J Med 3 (1973) 413-416
41. Dou H., Birusingh K., Faraci J., et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 23 (2003) 9162-9170
42. Dubas F., Gray F., and Escourolle R. Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases. Rev Neurol (Paris) 139 (1983) 407-416
43. Duncombe A.S., and Lees A.J. Methysergide in progressive supranuclear palsy. Neurology 35 (1985) 936-937
44. Engel P.A. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 44 (1996) 1072-1074
45. Esmonde T., Giles E., Xuereb J., et al. Progressive supranuclear palsy presenting with dynamic aphasia. J Neurol Neurosurg Psychiatry 60 (1996) 403-410
46. Fabbrini G., Barbanti P., Bonifati V., et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 103 (2001) 123-125
47. Factor S.A., Molho E.S., Feustel P.J., et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 24 (2001) 295-299
48. Federico F., Simone I.L., Lucivero V., et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62 (1997) 239-242
49. Federico F., Simone I.L., Lucivero V., et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov Disord 12 (1997) 903-909
50. Fjord-Larsen L., Johansen J.L., Kusk P., et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195 (2005) 49-60
51. Foster N.L., Aldrich M.S., Bluemlein L., et al. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 39 (1989) 257-261
52. Frampton M., Harvey R.J., and Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev 2 (2003) CD002853
53. Frattali C.M., Sonies B.C., Chi-Fishman G., et al. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy. A pilot study. Dysphagia 14 (1999) 165-168
54. Fujino Y., Nakajima M., Tsuboi Y., et al. [Clinical effectiveness of tandospirone citrate (5-HT1A agonist) on patients with progressive supranuclear palsy]. Rinsho Shinkeigaku 42 (2002) 42-44
55. Gash D.M., Zhang Z., Ai Y., et al. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 58 (2005) 224-233
56. Ghika J., Tennis M., Hoffman E., et al. Idazoxan treatment in progressive supranuclear palsy. Neurology 41 (1991) 986-991
57. Giladi N., Gurevich T., Shabtai H., et al. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol 248 (2001) 572-576
58. Goetz C.G., Olanow C.W., Koller W.C., et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 320 (1989) 337-341
59. Goetz C.G., Leurgans S., Lang A.E., et al. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 60 (2003) 917-922
60. Grafman J., Litvan I., Gomez C., et al. Frontal lobe function in progressive supranuclear palsy. Arch Neurol 47 (1990) 553-558
61. Gross M. L-dopa for progressive supranuclear palsy. Lancet 2 (1969) 1359-1360
62. Haldeman S., Goldman J.W., Hyde J., et al. Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs. Neurology 31 (1981) 442-445
63. Hardman C.D., and Halliday G.M. The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 14 (1999) 626-633
64. Hardman C.D., and Halliday G.M. The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease. Exp Neurol 158 (1999) 135-142
65. Haria M., Fitton A., McTavish D., et al. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4 (1994) 331-355
66. Hauser R.A., and Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord 9 (1994) 467-469
67. Hauw J.J., Daniel S.E., Dickson D., et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44 (1994) 2015-2019
68. Hughes A.J., Lees A.J., and Stern G.M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336 (1990) 32-34
69. Iannaccone S., and Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 19 (1996) 532-535
70. Iijima M., Terashi H., and Iwata M. [A case of progressive supranuclear palsy improved with tandospirone citrate]. Rinsho Shinkeigaku 41 (2001) 150-153
71. Izzo K.L., DiLorenzo P., and Roth A. Rehabilitation in progressive supranuclear palsy: case report. Arch Phys Med Rehabil 67 (1986) 473-476
72. Jackson J.A., Jankovic J., and Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 13 (1983) 273-278
73. Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology 33 (1983) 505-507
74. Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry 60 (1996) 704
75. Jenkins R. L-dopa for progressive supranuclear palsy. Lancet 2 (1969) 742
76. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29 (2004) 95-102
77. Kato E., Takahashi S., Abe T., et al. [A case of progressive supranuclear palsy showing improvement of rigidity, nuchal dystonia and autonomic failure with trazodone]. Rinsho Shinkeigaku 34 (1994) 1013-1017
78. Keating G.M., and Lyseng-Williamson K.A. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 19 (2005) 165-184
79. Kertzman C., Robinson D.L., and Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 47 (1990) 1346-1350
80. Kish S.J., Chang L.J., Mirchandani L., et al. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18 (1985) 530-536
81. Klawans Jr. H.L. L-dopa for progressive supranuclear palsy. Lancet 2 (1969) 1359
82. Koller W.C., Morantz R., Vetere-Overfield B., et al. Autologous adrenal medullary transplant in progressive supranuclear palsy. Neurology 39 (1989) 1066-1068
83. Koller W., Guarnieri M., Hubble J., et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 112 (2005) 221-230
84. Kompoliti K., Goetz C.G., Litvan I., et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 55 (1998) 1099-1102
85. Kovacs G.G., Kloppel S., Fischer I., et al. Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 14 (2003) 73-76
86. Kuhn A.A., Grosse P., Holtz K., et al. Patterns of abnormal motor cortex excitability in atypical parkinsonian syndromes. Clin Neurophysiol 115 (2004) 1786-1795
87. Kvale J.N. Amitriptyline in the management of progressive supranuclear palsy. Arch Neurol 39 (1982) 387-388
88. Laffont F., Leger J.M., Penicaud A., et al. Sleep abnormalities and evoked potentials (VEP-BAER-SEP) in progressive supranuclear palsy. Neurophysiol Clin 18 (1988) 255-269
89. Lang A.E. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 20 (2005) S83-S91
90. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
91. Levy R., Ruberg M., Herrero M.T., et al. Alterations of gabaergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology 45 (1995) 127-134
92. Limke T.L., and Rao M.S. Neural stem cell therapy in the aging brain: pitfalls and possibilities. J Hematother Stem Cell Res 12 (2003) 615-623
93. Lin W.L., Lewis J., Yen S.H., et al. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 162 (2003) 213-218
94. Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 21 (2001) 41-48
95. Litvan I., and Chase T. Traditional and Experimental Therapeutic Approaches (1992), Oxford University Press, Oxford
96. Litvan I., Gomez C., Atack J.R., et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 26 (1989) 404-407
97. Litvan I., Blesa R., Clark K., et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 36 (1994) 55-61
98. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) report of the NINDS-SPSP international workshop. Neurology 47 (1996) 1-9
99. Litvan I., Sastry N., and Sonies B.C. Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology 48 (1997) 1654-1662
100. Litvan I., Paulsen J.S., Mega M.S., et al. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 55 (1998) 1313-1319
101. Litvan I., Phipps M., Pharr V.L., et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57 (2001) 467-473
102. Losada Baltar A., Izal Fernandez de Troconiz M., Montorio Cerrato I., et al. [Differential efficacy of two psychoeducational interventions for dementia family caregivers]. Rev Neurol 38 (2004) 701-708
103. Marra M., Toni V., Trianni G., et al. Progressive supranuclear palsy: analysis of six cases. Neurol Sci 24 (2003) 186-187
104. Mattson M.P., Fu W., Waeg G., et al. 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 8 (1997) 2275-2281
105. Mayr B.J., Bonelli R.M., Niederwieser G., et al. Zolpidem in progressive supranuclear palsy. Eur J Neurol 9 (2002) 184-185
106. Mendell J.R., Engel W.K., and Chase T.N. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet 1 (1970) 593-594
107. Metter E.J., and Hanson W.R. Clinical and acoustical variability in hypokinetic dysarthria. J Commun Disord 19 (1986) 347-366
108. Morariu M.A. Progressive supranuclear palsy and normal-pressure hydrocephalus. Neurology 29 (1979) 1544-1546
109. Muller J., Wenning G.K., Wissel J., et al. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249 (2002) 300-304
110. Nagasaka T., Togashi S., Amino A., et al. Aniracetam for treatment of patients with progressive supranuclear palsy. Eur Neurol 37 (1997) 195-198
111. Nakashima H., Ishihara T., Suguimoto P., et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol (Berl) 110 (2005) 547-556
112. Nath U., Ben-Shlomo Y., Thomson R.G., et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 60 (2003) 910-916
113. Neophytides A., Lieberman A.N., Goldstein M., et al. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 45 (1982) 261-263
114. Netzel P.J., and Sutor B. Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy. J Ect 17 (2001) 68-70
115. Newman G.C. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 35 (1985) 1189-1193
116. Nieforth K.A., and Golbe L.I. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16 (1993) 338-346
117. Nitrini R. Elementary motor perservation in early diagnosis of progressive supranuclear palsy. Arq Neuropsiquiatr 45 (1987) 29-32
118. Noble W., Planel E., Zehr C., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102 (2005) 6990-6995
119. Nutt J.G., Burchiel K.J., Comella C.L., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
120. Odetti P., Garibaldi S., Norese R., et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 59 (2000) 393-397
121. Okun M.S., Tagliati M., Pourfar M., et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 62 (2005) 1250-1255
122. Olanow C.W. Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. Arch Neurol 62 (2005) 1343-1344
123. Ondo W.G., Hunter C., and Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62 (2004) 37-40
124. Ota S., and Tsuchiya K. Pure akinesia presenting with antecollis. No To Shinkei 57 (2005) 893-898
125. Paija O., Laine K., Kultalahti E.R., et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 28 (2005) 115-119
126. Papapetropoulos S., Gonzalez J., and Mash D.C. Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 54 (2005) 1-9
127. Parkes J.D., Schachter M., Marsden C.D., et al. Lisuride in parkinsonism. Ann Neurol 9 (1981) 48-52
128. Pascual J., Berciano J., Gonzalez A.M., et al. Autoradiographic demonstration of loss of alpha 2-adrenoceptors in progressive supranuclear palsy: preliminary report. J Neurol Sci 114 (1993) 165-169
129. Patel N.K., Bunnage M., Plaha P., et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57 (2005) 298-302
130. Paulson G.W., Lowery H.W., and Taylor G.C. Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide. Eur Neurol 20 (1981) 13-16
131. Perkin G.D., Lees A.J., Stern G.M., et al. Problems in the diagnosis of progressive supranuclear palsy. (Steele-Richardson-Olszewski syndrome). Can J Neurol Sci 5 (1978) 168-173
132. Pfaffenbach D.D., Layton Jr. D.D., and Kearns T.P. Ocular manifestations in progressive suprauclear palsy. Am J Ophthalmol 74 (1972) 1179-1184
133. Pinhas I., Pinhas A., Goldhammer Y., et al. Progressive supranuclear palsy: electomyographic examinations of eyes muscles. Acta Neurol Scand 58 (1978) 304-308
134. Plaha P., and Gill S.S. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport 16 (2005) 1883-1887
135. Rafal R.D., and Grimm R.J. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology 31 (1981) 1507-1518
136. Rascol O., Sieradzan K., Peyro-Saint-Paul H., et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 13 (1998) 673-676
137. Reynolds N.A., Wellington K., and Easthope S.E. Rotigotine: in Parkinson's disease. CNS Drugs 19 (2005) 973-981
138. Sacks O.W. L-dopa for progressive suparanuclear palsy. Lancet 2 (1969) 591-592
139. Sandyk R. Transcranial AC pulsed applications of weak electromagnetic fields reduces freezing and falling in progressive supranuclear palsy: a case report. Int J Neurosci 94 (1998) 41-54
140. Sandyk R., and Snider S.R. Naloxone in progressive supranuclear palsy. Clin Neuropharmacol 8 (1985) 198-199
141. Sanftner L.M., Sommer J.M., Suzuki B.M., et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol 194 (2005) 476-483
142. Schainker B.A. Autopsy diagnosis of progressive supranuclear palsy mistaken clinically for stroke. Case report. Mo Med 75 (1978) 227-229
143. Schneider L.S., Gleason R.P., and Chui H.C. Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine. J Geriatr Psychiatry Neurol 2 (1989) 109-112
144. Shinotoh H., Namba H., Yamaguchi M., et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 46 (1999) 62-69
145. Shinotoh H., Namba H., Yamaguchi M., et al. In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy. Adv Neurol 86 (2001) 249-255
146. Silveira-Moriyama L., Goncalves L.R., Chien H.F., et al. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr 63 (2005) 221-224
147. Skogseid I.M., and Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12 (2005) 163-170
148. Steele J.C., Richardson J.C., and Olszewski J. Progressive supranuclear palsy. a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10 (1964) 333-359
149. Stefani A., Lozano A.M., Peppe A., et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 130 (2007) 1596-1607
150. Sugaya K. Neuroreplacement therapy and stem cell biology under disease conditions. Cell Mol Life Sci 60 (2003) 1891-1902
151. Suteerawattananon M., MacNeill B., and Protas E.J. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy. Phys Ther 82 (2002) 485-495
152. Tamai S., and Almeida O.P. Nortriptyline for the treatment of depression in progressive supranuclear palsy. J Am Geriatr Soc 45 (1997) 1033-1034
153. Tedeschi G., Litvan I., Bonavita S., et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 120 (1997) 1541-1552
154. Tetrud J.W., Golbe L.I., Forno L.S., et al. Autopsy-proven progressive supranuclear palsy in two siblings. Neurology 46 (1996) 931-934
155. Tuszynski M.H., Thal L., Pay M., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11 (2005) 551-555
156. Wagshul A., and Daroff R.B. L-dopa for progressive supranuclear palsy. Lancet 2 (1969) 105-106
157. Uttl B., Santacruz P., Litvan I., et al. Caregiving in progressive supranuclear palsy. Neurology 51 (1998) 1303-1309
158. Vu T.Q., Ling Z.D., Ma S.Y., et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 107 (2000) 159-176
159. Van Balken I., and Litvan I. Current and future treatments in progressive supranuclear palsy. Curr Treat Options Neurol 8 (2006) 211-223
160. Ward-Smith P.A., and Berry P. Autologous transplantation as a treatment for progressive supranuclear palsy. J Neurosci Nurs 22 (1990) 100-103
161. Weiner W.J., Minagar A., and Shulman L.M. Pramipexole in progressive supranuclear palsy. Neurology 52 (1999) 873-874
162. Whitehouse P.J., Martino A.M., Marcus K.A., et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45 (1988) 722-724
163. Williams A.C., Nutt J., Lake C.R., et al. Actions of bromocriptine in the Shy-Drager and Steele-Richardson-Olszewski syndromes. In: Fuxe K., and Calne D.B. (Eds). Dopaminergic Ergot Derivatives and Motor Function (1979), Pergamon Press, Oxford 271-283
164. Yamamoto M., Fujii S., and Hatanaka Y. Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy. Clin Neuropharmacol 20 (1997) 371-373
165. Yamashi M., Sanada J., Miyazaki Y., et al. [Short-term treatment of progressive supranuclear palsy with amitriptyline]. Rinsho Shinkeigaku 26 (1986) 1138-1141
166. Yokoji I., Nakamura S., and Ikeda T. [A case of progressive supranuclear palsy associated with bilateral vocal cord abductor paralysis]. Rinsho Shinkeigaku 37 (1997) 523-525
167. Yoshikawa H., Oda Y., Sakajiri K., et al. Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy. Acta Neuropathol (Berl) 93 (1997) 306-309
168. Youdim M.B., and Riederer P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 63 (2004) S32-S35
169. Young A.B. Progressive supranuclear palsy: postmortem chemical analysis. Ann Neurol 18 (1985) 521-522
170. Yukitake M., Takashima Y., Kurohara K., et al. Improvement of ophthalmoplegia by 5-hydroxytryptophan in two cases of progressive supranuclear palsy. Rinsho Shinkeigaku 36 (1996) 906-908
171. Zou L., Xu J., Jankovic J., et al. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 281 (2000) 167-170